Haizheng Pharmaceutical announced that the National Health Commission issued a notice on July 9, 2026, and the “National Essential Drug Catalogue” will come into effect on September 1. The company and its wholly-owned subsidiary Hanhui Pharmaceutical have a total of 5 new products added to the catalogue, and no products have been withdrawn. New products include indatroglone ammonium bromide inhalation powder, etc. The selection will help expand the coverage of the product in the primary care market. It has positive significance for the long-term strategic layout, but it will not have a significant impact on current results, and the sales situation is uncertain.

Haizheng Pharmaceutical announced that the National Health Commission issued a notice on July 9, 2026, and the “National Essential Drug Catalogue” will come into effect on September 1. The company and its wholly-owned subsidiary Hanhui Pharmaceutical have a total of 5 new products added to the catalogue, and no products have been withdrawn. New products include indatroglone ammonium bromide inhalation powder, etc. The selection will help expand the coverage of the product in the primary care market. It has positive significance for the long-term strategic layout, but it will not have a significant impact on current results, and the sales situation is uncertain.